Federal contractor · public award history
ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE)
DBA SABIN VACCINE INSTITUTE
Parent: ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE) Unique Entity Identifier (UEI)H5E8NU6N2HZ5
- Awards we know about
- 2
- Typical size
- $152.94M
- Middle of their public awards
- Dollars on those awards
- $305.87M
Most of their awards we can see fall roughly between $150.00M and $155.87M.
SAM.gov registration
- Status
- Active
- Purpose of registration
- All awards (Z2)
- Registration expires
- Apr 6, 2027
- Activation date
- Apr 14, 2026
Other NAICS on file
Business types (SAM)
Registration fields from the official SAM.gov public entity extract (monthly bulk). Not a substitute for live SAM checks.
Continue contractor research
Use the verified identifiers and public award record to investigate documented incumbents, compare competitors, or identify possible teaming partners. This is a research starting point, not a capability or partner recommendation.
These official USAspending contract records do not rate capability or past performance and do not tell you whether to team or bid.
Awarding agencies
- Department of Health and Human Services (2)
Industries & product codes
Award history
- Department of Health and Human Services$158.81MJul 29, 2025Procurement Instrument Identifier (PIID)75A50123C00010Research and Development in Biotechnology (except Nanobiotechnology)541714Health R&D Services; Health Care - Other; Applied ResearchAN42Contract awardUSAspending ↗
THE SCOPE OF THE PROPOSED PROGRAM INCLUDES MANUFACTURE OF SABIN?S SUDAN EBOLAVIRUS VACCINE (BULK DRUG SUBSTANCE (BDS) AND FINAL DRUG PRODUCT (FDP)) TO PROVIDE DOSES THAT MAY BE USED IN THE EVENT OF AN OUTBREAK SCENARIO. THE PROPOSED EFFORT WILL UTILI
- Department of Health and Human Services$147.06MMay 6, 2025Procurement Instrument Identifier (PIID)75A50119C00055Research and Development in Biotechnology (except Nanobiotechnology)541714R&D- Medical: Specialized Medical Services (Advanced Development)AN73Contract awardUSAspending ↗
THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE.
For research only. This is not legal advice, a past-performance review, or a recommendation to team or bid. Check USAspending and SAM.gov.